Scientists explored the differences in heart inflammation caused by COVID-19, anti-COVID-19 vaccines, and other viral ...

For a majority of people, the COVID vaccine doesn’t cause adverse health effects — but a small percentage experience chronic ...

Pemgarda has a standing emergency use authorization as a prophylaxis for immunocompromised patients, but FDA’s stringent ...

The finding that the vaccines substantially reduce the risk of long COVID in kids echoes findings seen in studies on adults.

A small study on Covid vaccine safety has sparked an online tempest — and highlighted the conundrum faced by some scientists.

FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent ...

These two stocks are poised to crush the market thanks to their outsize growth prospects and dirt cheap valuations.

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...

Paxlovid may not decrease the risk for hospitalization or death in older adults vaccinated against COVID-19 as much as ...